HIV drug that awakens latent infection soon to be tested in humans

According to Bloomberg, in the UK, the pharmaceutical company GlaxoSmithKline is ready to begin clinical trials of a fundamentally new HIV drug.

British multinational pharmaceutical company GlaxoSmithKline plans to begin human trials of an HIV drug as early as next summer. The company has previously completed clinical studies in primates.

Two weeks before the news of the drug’s pending trials was revealed, the National Institute for Health and Clinical Excellence (NICE) of the UK Department of Health approved an antiretroviral drug for HIV therapy called Cabotegravir from GlaxoSmithKline. Unlike traditional antiretroviral therapy, which must be taken every day, the UK drug must be injected monthly or every two months.

According to The Telegraph, the company will begin testing the therapy in humans to awaken the latent HIV virus in people’s immune cells. “The idea is that you have to wake up the hidden virus and try to get rid of it,” explains Dr. Kimberly Smith, head of research and development at ViiV Healthcare, GSK’s HIV division. This approach has already been tested on non-human primates.

More than 38 million people worldwide are living with HIV or the Human Immunodeficiency Virus, which causes AIDS. Decades later, HIV is no longer a death sentence: medications help people with the disease live longer, healthier lives by reducing the risk of transmission. However, the stigma surrounding the disease still persists.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Alexandr Ivanov earned his Licentiate Engineer in Systems and Computer Engineering from the Free International University of Moldova. Since 2013, Alexandr has been working as a freelance web programmer.
Function: Web Developer and Editor
E-mail: except.freenews@gmail.com
Alexandr Ivanov

Spelling error report

The following text will be sent to our editors: